Question 1

What was CORONA Remedies' net profit in Q2 FY27?

Accepted Answer

Consolidated net profit was ₹60.3 crore, up 15.3% from ₹52.3 crore in Q2 FY26 and up 0.3% from ₹60.1 crore in Q1 FY27.

Question 2

How were CORONA Remedies' Q2 FY27 results?

Accepted Answer

Both grew from a year earlier: net profit was up 15.3% at ₹60.3 crore and revenue was up 22.2% at ₹441 crore. The operating margin was 18.3%, down 0.8 percentage points from 19.2% a year earlier. Against Q1 FY27, net profit was up 0.3% and revenue up 4.4%.

Question 3

What is CORONA Remedies' net profit margin?

Accepted Answer

CORONA Remedies' net profit margin was 13.7% in Q2 FY27 (net profit as a share of revenue from operations), against 14.5% in Q2 FY26 (down 0.8 percentage points). For FY26 as a whole it was 13.2%.

Question 4

What was CORONA Remedies' revenue in Q2 FY27?

Accepted Answer

Revenue from operations was ₹441 crore, up 22.2% year on year and up 4.4% from the previous quarter.

Question 5

What was CORONA Remedies' EPS in Q2 FY27?

Accepted Answer

Basic earnings per share were ₹9.86, against ₹8.55 in Q2 FY26.

Question 6

What was CORONA Remedies' net profit in FY26?

Accepted Answer

Consolidated net profit was ₹185 crore in FY26 (April 2025–March 2026).

Question 7

What was CORONA Remedies' operating margin in Q2 FY27?

Accepted Answer

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹80.9 crore, a margin of 18.3%, against 18.9% in Q1 FY27 and 19.2% in Q2 FY26. EBITDA was ₹96 crore, 21.7% of revenue.

Question 8

How has CORONA Remedies' profit changed over the last four quarters?

Accepted Answer

Net profit by quarter: ₹41.3 crore in Q3 FY26, ₹45.3 crore in Q4 FY26, ₹60.1 crore in Q1 FY27 and ₹60.3 crore in Q2 FY27. That is ₹207 crore over the four quarters. Revenue from operations: ₹342 crore, ₹353 crore, ₹422 crore and ₹441 crore.

Question 9

When did CORONA Remedies announce its Q2 FY27 results?

Accepted Answer

On Friday, 30 October 2026 at 6:35 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 2 January 2026.

Question 10

What was CORONA Remedies' revenue in FY26?

Accepted Answer

Revenue from operations was ₹1,403 crore in FY26 (April 2025–March 2026).

Question 11

When will CORONA Remedies announce its Q3 FY27 results?

Accepted Answer

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Question 12

Where do these CORONA Remedies figures come from?

Accepted Answer

From CORONA Remedies' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 30 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	441	361	+22.2%
EBITDA	96.0	78.5	+22.3%
EBITDA margin	21.8%	21.7%	0.0 pts
Profit before tax	80.6	69.6	+15.8%
Net profit	60.3	52.3	+15.3%
EPS	₹9.86	₹8.55	+15.3%

Expenses
	441	422	353	342	361
	2.5	3.2	4.1	2.2	2.3
	444	426	357	345	363
	35.0	32.7	27.7	24.8	25.9
	68.2	57.2	46.3	41.2	28.1
	−22.7	−12.3	−7.8	−5.7	14.6
	124	122	107	95.9	103
	2.8	2.7	1.4	1.7	1.9
	15.1	13.2	10.3	9.5	9.2
	140	130	118	103	111
	363	345	303	270	294
	96.0	93.1	62.0	83.2	78.5
	80.9	79.9	51.7	73.7	69.3
Profit
	80.6	80.4	54.5	74.3	69.6
	0.0	0.0	0.3	−19.1	0.0
	80.6	80.4	54.7	55.2	69.6
	18.4	18.4	4.2	17.1	15.9
	2.0	1.9	5.2	−3.2	1.6
	20.4	20.3	9.4	13.9	17.5
	0.1	0.0	0.0	0.0	0.2
	60.3	60.1	45.3	41.3	52.3
	60.2	60.1	45.3	41.3	52.2
	−0.7	−0.3	0.7	−0.1	0.3
	59.6	59.8	46.0	41.2	52.6
	60.3	60.1	45.3	41.3	52.3
Per share
	₹9.86	₹9.83	₹7.41	₹6.75	₹8.55
	₹9.86	₹9.83	₹7.41	₹6.75	₹8.55
Other comprehensive income — detail
	−0.7	−0.3	0.7	−0.1	0.3
	—	—	—	—	0.4
	0.7	0.3	−0.7	0.1	0.1
	59.6	−0.3	0.7	−0.1	52.6
Per share — as-filed variants
	₹9.86	₹9.83	₹7.41	₹6.75	₹8.55
	₹9.86	₹9.83	₹7.41	₹6.75	₹8.55
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	361	345	287	282	292
	81.8%	81.6%	81.2%	82.4%	81.0%
Adjusted (ex-exceptional items) — derived
	80.6	80.4	54.5	74.3	69.6
	0.0	0.0	0.3	−19.1	0.0
	60.3	60.1	45.1	55.5	52.3
	₹9.86	₹9.83	₹7.37	₹9.08	₹8.55

In ₹ Crore except Per Share 3 Months Ending	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	361.1	342.4	353.1	422.4	441.2
Other Income	2.3	2.2	4.1	3.2	2.5
Total Income	363.4	344.7	357.2	425.6	443.7
Expenses
+ Cost of Materials Consumed	25.9	24.8	27.7	32.7	35.0
+ Purchases of Stock-in-Trade	28.1	41.2	46.3	57.2	68.2
+ Changes in Inventories	14.6	-5.7	-7.8	-12.3	-22.7
+ Employee Benefit Expense	103.0	95.9	106.6	122.1	124.2
+ Finance Costs	1.9	1.7	1.4	2.7	2.8
+ Depreciation & Amortisation	9.2	9.5	10.3	13.2	15.1
+ Other Expenses	111.0	103.1	118.2	129.7	140.5
Total Expenses	293.8	270.4	302.7	345.2	363.0
EBITDA	78.5	83.2	62.0	93.1	96.0
EBIT	69.3	73.7	51.7	79.9	80.9
Profit
PBT before Exceptional Items	69.6	74.3	54.5	80.4	80.6
+ Exceptional Items	0.0	-19.1	0.3	0.0	0.0
Pretax Income	69.6	55.2	54.7	80.4	80.6
+ Current Tax	15.9	17.1	4.2	18.4	18.4
+ Deferred Tax	1.6	-3.2	5.2	1.9	2.0
Tax Expense	17.5	13.9	9.4	20.3	20.4
+ Share of Associates & JVs	0.2	0.0	0.0	0.0	0.1
Net Income	52.3	41.3	45.3	60.1	60.3
+ Net Income — Continuing Ops	52.2	41.3	45.3	60.1	60.2
+ Other Comprehensive Income	0.3	-0.1	0.7	-0.3	-0.7
Total Comprehensive Income	52.6	41.2	46.0	59.8	59.6
Net Income to Common	52.3	41.3	45.3	60.1	60.3
Per Share
Basic EPS	8.55	6.75	7.41	9.83	9.86
Diluted EPS	8.55	6.75	7.41	9.83	9.86
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.3	-0.1	0.7	-0.3	-0.7
+ Items NOT to be Reclassified to P&L	0.4	—	—	—	—
+ Tax on Items NOT to be Reclassified	0.1	0.1	-0.7	0.3	0.7
Comprehensive Income — Owners of Parent	52.6	-0.1	0.7	-0.3	59.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	8.55	6.75	7.41	9.83	9.86
Diluted EPS — Continuing Operations	8.55	6.75	7.41	9.83	9.86
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	292.5	282.2	286.9	344.9	360.7
Gross Margin %	80.99	82.40	81.24	81.65	81.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	69.6	74.3	54.5	80.4	80.6
− Exceptional Items (reconciliation)	0.0	-19.1	0.3	0.0	0.0
Net Income Adj (tax-effected)	52.3	55.5	45.1	60.1	60.3
EPS Adj	8.55	9.08	7.37	9.83	9.86
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	61.2	61.2	61.2	61.2	61.2

CORONA Remedies quarterly results

Every quarter

CORONA Remedies Ltd.

CORONA Remedies Q2 FY27 results (July–September 2026)

Q2 FY27 at a glance · consolidated

Questions